Baxter International Inc. · NYSE:BAX
Baxter International — 2018 Baxter Investor Conference
14 slides from Baxter International's conference presentation, May 21, 2018
Slide 1: Clinical Nutrition
CLINICAL NUTRITION Jorge Vasseur GM, Clinical Nutrition May 21, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter’s financial results, R&D pipeline, including planned product launches (many of which are subject to regulatory approval) and results of clinical trials, business development activities, capital structure, c
Slide 3: Parenteral Nutrition (PN) Market Overview
Parenteral Nutrition (PN) Market Overview1 Global Market Size Micronutrients CAGR2 ~$5.1B Vitamins and Trace Elements #1 ~$4.3B 3% - 4% Baxter Position 4% - 5% Automated Compounding Automixers, software, disposables and compounding services #1 Baxter 2% - 3% Position Macronutrients Lipids, Amino Aci
Slide 4: Parenteral Nutrition Market Dynamics
Parenteral Nutrition Market Dynamics ~70% 40% Critically Ill Hospitalized Receive Suboptimal Patients Suffer From Nutrition2 Malnutrition1 Many diagnosed patients are 80% go undiagnosed “underfed” 15 Million 1.8 Million Pre-term Infants Born Per Cancer Patients Die From Year3 Malnutrition Annually4
Slide 5: Clinical Nutrition Portfolio
Clinical Nutrition Portfolio Automated Compounding Macronutrients 26% Ready-to-use MCBs: OLIMEL, NUMETA 53% $882M EXACTAMIX 2017 Sales 21% Micronutrients Amino Acids & Lipids: CLINOSOL, CLINOLEIC CERNEVIT INFUVITE Broad Nutritional Portfolio To Meet The Unique Needs Of Patients | 5
Slide 6: Strategic Growth Drivers
Strategic Growth Drivers Portfolio Innovation Market Development Enter Adjacencies ~$120M Generate clinical evidence to show broader benefits Targeted products for 2023 New Product Revenue1 pre-term infants of PN Accelerate launch cadence and expand Increase adoption of Drive therapy adoption nutrit
Slide 7: Clinical Nutrition Pipeline
Portfolio Market Enter Clinical Nutrition Pipeline Innovation Development Adjacencies Trace Elements Numeta G13 Olimel N12 Finomel Numeta G13 Emerging Markets Emerging Markets Emerging Markets Emerging Markets China Olimel Olimel N12 Clinimix HP Clinimix SubQ Trace Elements Emerging Markets EMEA U.S
Slide 8: Key Launches
Portfolio Market Enter Key Launches Innovation Development Adjacencies Olimel N12 Highest protein & lowest glucose content of any Higher protein content is associated 3CB1 on the market with clinically significant improvements in patient outcomes Clinimix HP 60% more protein than any other 2CB2 on t
Slide 9: Market Development
Portfolio Market Enter Market Development Innovation Development Adjacencies Clinical Evidence Peer-to-Peer Educational Generation Programs $10M investment to support Sustained investment reaching therapy adoption & differentiation1 7,000 clinicians by 2023 Optimal feeding through supplemental 3X in
Slide 10: Enter Adjacencies
Portfolio Market Enter Enter Adjacencies Innovation Development Adjacencies Clinical Need Baxter Solution Drive standardized, ready-to- Neonatal use PN as first line therapy Numeta G13 Nutrition for pre-term infants Timely initiation of PN in Nutrition In oncology improves functional and clinical Ra
Slide 11: Transformative Innovation
Transformative Innovation Novel Formulations Explore new formulations that deliver superior clinical outcomes: Lipid & Amino Acid blends that increase recovery & improve growth Clinical Nutrition Innovation Roadmap Improved Prep and Delivery Advancements to Enhance Care Advance technology to deliver
Slide 12: Clinical Nutrition Summary
Clinical Nutrition Summary Innovating in ready-to-use MCBs to deliver above-market growth of 4% - 5% through 20231 Investing in evidence generation and education to drive therapy adoption and sustained base business growth Delivering optimal nutrition to adjacent patient populations to expand growth
Slide 13: References
References Market Dynamics (Slide 4) 1) Norman K, et al. Clin Nutr 2008;27:5-15. 2011. 2) Barker LA, National Institute of Health 3) Althabe F, Howson CP, Kinney M, Lawn J, World Health Organization 2012 4) Silva FR. et al. Nutrition Journal . 2015 Key Launches (Slide 8) 1) Represents Three-Chamber
Slide 14: 2018 Investor Conference
— 2018 Investor Conference a
Baxter International — 2018 Baxter Investor Conference on 6ix